ArticleKidney international reports2026
Clinical Value of Kidney Immunodeposits and Urinary Complement Activation Fragments in IgAN.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High complement activation index predicts renal progression in crescentic IgA nephropathy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: Ig deposits and complement activation are central in the pathogenesis of IgA nephropathy (IgAN). Whether immunodeposits, assessed by immunofluorescence (IF) and electron microscopy (EM), or the measurement of urinary complement activation fragments, can help determine the likelihood of progression of IgAN is unknown. Methods: In this retrospective analysis of 247 patients of IgAN with pathology assessments and clinical follow-up from the Cure Glomerulonephropathy (CureGN) cohort, we assessed immunodeposits by IF (intensity and localization of IgA, C3, IgG, and IgM) and EM (quantity and localization of deposits and foot process effacement [FPE]), as well as urinary membrane attack complex at enrollment (soluble C5b9 [sC5b9]). We tested associations between immunodeposits and urinary sC5b9 with light microscopy (LM) with proteinuria and survival from kidney failure or a ≥ 40% decline in estimated glomerular filtration rate (eGFR; combined outcome). Results: Mesangial and endocapillary hypercellularity and crescents were associated with IgA and C3 capillary localization by IF. Mesangial and endocapillary hypercellularity also correlated with IgA and C3 staining intensity by IF, and immunodeposits intensity and degree of FPE by EM. In 115 incident subjects enrolled within 6 months of their kidney biopsy, proteinuria and urinary sC5b9 were associated with IgA and C3 capillary deposition by IF, as well as the quantity of subendothelial deposits by EM. Finally, proteinuria and urinary sC5b9 were each independently associated with a combined outcome and showed an interaction when both were elevated. Conclusion: In IgAN, the amount and localization of immunodeposits correlated with proliferative lesions and urinary sC5b9. In turn, the urinary membrane attack complex was independently associated with loss of eGFR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.